ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $80.13 Average Price Target from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) has received a consensus recommendation of "Buy" from the nine research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $80.13.

A number of analysts have recently commented on the company. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 price target on the stock. Truist Financial boosted their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a report on Monday, April 21st. Wall Street Zen lowered ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Guggenheim reaffirmed a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th.

ANI Pharmaceuticals Trading Up 0.7%

Shares of NASDAQ:ANIP traded up $0.47 during midday trading on Friday, hitting $66.03. The company had a trading volume of 179,572 shares, compared to its average volume of 312,628. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $77.00. The company has a current ratio of 2.66, a quick ratio of 1.98 and a debt-to-equity ratio of 1.46. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -51.99 and a beta of 0.55. The firm has a fifty day simple moving average of $64.57 and a 200 day simple moving average of $61.43.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. The company had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. The company's quarterly revenue was up 43.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.82 earnings per share. On average, analysts predict that ANI Pharmaceuticals will post 3.86 EPS for the current year.

Insiders Place Their Bets

In related news, SVP Ori Gutwerg sold 881 shares of the business's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $60.07, for a total value of $52,921.67. Following the completion of the sale, the senior vice president now directly owns 89,897 shares in the company, valued at $5,400,112.79. The trade was a 0.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Meredith Cook sold 400 shares of the company's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $68.96, for a total value of $27,584.00. Following the completion of the transaction, the vice president now directly owns 80,145 shares in the company, valued at approximately $5,526,799.20. This represents a 0.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,681 shares of company stock valued at $346,854 over the last 90 days. 12.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ANIP. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of ANI Pharmaceuticals by 14.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company's stock worth $854,000 after purchasing an additional 1,972 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of ANI Pharmaceuticals by 6.6% in the fourth quarter. Victory Capital Management Inc. now owns 13,777 shares of the specialty pharmaceutical company's stock valued at $762,000 after buying an additional 858 shares during the period. US Bancorp DE boosted its stake in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after buying an additional 531 shares during the period. GAMMA Investing LLC boosted its stake in shares of ANI Pharmaceuticals by 17,558.4% in the first quarter. GAMMA Investing LLC now owns 95,002 shares of the specialty pharmaceutical company's stock valued at $6,360,000 after buying an additional 94,464 shares during the period. Finally, Natixis Advisors LLC boosted its stake in shares of ANI Pharmaceuticals by 2.3% in the fourth quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock valued at $1,028,000 after buying an additional 417 shares during the period. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.